John Libbey Eurotext



Les vaccins de demain Volume 13, numéro 3, Mars 2017

  • [1] Henao-Restrepo A.M., Camacho A., Longini I.M. Efficacy and effectiveness of an rVSV-vectoredvaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet. 2017;389:505-518.
  • [2] Hadinegoro S.R., Arredondo-García J.L., Capeding M.R. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med. 2015;373:1195-1206.
  • [3] Vesikari T., Esposito S., Prymula R. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet. 2013;381:825-835.
  • [4] Lehtinen M., Paavonen J., Wheeler C.M. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia : 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13:89-99.
  • [5] Cunningham A.L., Lal H., Kovac M. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med. 2016;375:1019-1032.
  • [6] Lindsey B., Kampmann B., Jones C. Maternal immunization as a strategy to decrease susceptibility to infection in newborn infants. Curr Opin Infect Dis. 2013;26:248-253.
  • [7] Saso A., Kampmann B. Vaccination against respiratory syncytial virus in pregnancy: a suitable tool to combat global infant morbidity and mortality? Lancet Infect Dis. 2016;16:e153-e163.
  • [8] Heyderman R.S., Madhi S.A., French N. Group B streptococcus vaccination in pregnant women with or without HIV in Africa : a non-randomised phase 2, open-label, multicentre trial. Lancet Infect Dis. 2016;16:546-555.
  • [9] DiazGranados C.A., Dunning A.J., Kimmel M. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371:635-645.
  • [10] Ghose C., Kelly C.P. The Prospect for Vaccines to Prevent Clostridium difficile Infection. Infect Dis Clin North Am. 2015;29:145-162.
  • [11] Vincent J.-L. Vaccine development and passive immunization for Pseudomonas aeruginosa in critically ill patients : a clinical update. Future Microbiol. 2014;9:457-463.